Stephen Hanauer to Europe
This is a "connection" page, showing publications Stephen Hanauer has written about Europe.
Connection Strength
0.781
-
The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2023 Jul-Dec; 19(9):1075-1089.
Score: 0.206
-
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 10; 6(10):816-825.
Score: 0.182
-
Perspectives of Clinicians in the United States and Europe on Monitoring Levels of Biologic Agents in Patients Receiving Biologic Therapies for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 08; 17(9):1718-1723.
Score: 0.158
-
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3.
Score: 0.080
-
European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut. 2007 Feb; 56(2):161-3.
Score: 0.067
-
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3.
Score: 0.028
-
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201.
Score: 0.023
-
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520.
Score: 0.020
-
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008 Aug; 135(2):400-9.
Score: 0.018